Regeneron’s phase 3 melanoma program for its LAG-3 inhibitor missed its primary endpoint, leaving the company facing a second late-stage failure for a key program after a setback within the past year. Analysts described the result as a blow to expectations that the therapy could outperform or provide a competitive alternative to pembrolizumab (Keytruda) in the studied setting. The failure raises pressure on Regeneron’s pipeline prioritization and next-step strategy for LAG-3 and combination approaches. For the sector, the read-through is a reminder that immuno-oncology remains outcome-sensitive in pivotal trials, and companies are likely to scrutinize patient selection, comparator logic, and trial endpoints even more closely ahead of future submissions.